These results exhibit that combined inhibition of EGFR and aberrantly activated MAP kinase signaling pathway by drugs would be very effective against a subset of colon cancer cell lines including cetuximab-refractory KRAS or BRAF mutation-bearing cells. This evidence concerns the gene EGFR and colonic neoplasm.